Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:

• Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC
• Incorporating newly approved immunotherapies into practice
• Evolving guidelines and recommendations for biomarker testing  
• RNA- vs DNA-based next-generation sequencing
• Interpretation of NGS results
• Use of frontline TKI therapy for patients with CNS metastases
• Future role of KRAS inhibitors in the treatment of advanced NSCLC
• Improving rates of biomarker testing in lung cancer

Presenters:

Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen V. Liu, MD
Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Supported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3npjyyb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.